
    
      This is an open-label, phase II trial of PTK787/ZK 222584. Patients will receive 750 mg daily
      for one week, 1000 mg daily for the second week, and then 1250 mg per day thereafter.

      Response Assessment: In the absence of toxicity or clinical progression, patients will remain
      in the study until their PSA (Prostate-specific Antigen) has doubled from pretreatment
      baseline.
    
  